Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myeloproliferative Disorders 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Congenital Abnormalities 1Carcinoma, Non-Small-Cell Lung 1Anemia, Refractory, with Excess of Blasts 1

Interventions

fludarabine phosphate 42Cyclophosphamide 37Busulfan 31Cyclosporine 30Peripheral Blood Stem Cell Transplantation 29Cytarabine 27Mycophenolic Acid 25Antilymphocyte Serum 23Filgrastim 22Methotrexate 20Whole-Body Irradiation 18Radiotherapy 17Tacrolimus 16Methylprednisolone 13Etoposide 12Cord Blood Stem Cell Transplantation 12Melphalan 11Daunorubicin 10sargramostim 8fludarabine 8Idarubicin 8Granulocyte Colony-Stimulating Factor 8Thiotepa 6Cyclosporins 6tipifarnib 5merphos 5Topotecan 5Mitoxantrone 5Gemtuzumab 5Azacitidine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Anemia, Refractory, with Excess of Blasts × Drug Screening Assays, Antitumor × Clear all
NCT01872819 2018-07-11

Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay

University of Washington

Phase NA Completed
16 enrolled 9 charts
Classical hematologyMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡